Cancer Therapy

You have full text access to this OnlineOpen article

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

  1. Michael Stanglmaier1,
  2. Margot Faltin1,
  3. Peter Ruf1,
  4. Annette Bodenhausen1,
  5. Petra Schröder3,
  6. Horst Lindhofer1,2,†,*

Article first published online: 10 JUN 2008

DOI: 10.1002/ijc.23626

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1181–1189, 1 September 2008

Additional Information

How to Cite

Stanglmaier, M., Faltin, M., Ruf, P., Bodenhausen, A., Schröder, P. and Lindhofer, H. (2008), Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int. J. Cancer, 123: 1181–1189. doi: 10.1002/ijc.23626

Author Information

  1. 1

    TRION Research GmbH, Martinsried, Germany

  2. 2

    TRION Pharma GmbH, Munich, Germany

  3. 3

    EUFETS AG, Idar-Oberstein, Germany

  1. †

    Fax: +49-89-324-266-199.

*TRION Pharma GmbH, Frankfurter Ring 193a, D-80807 Munich, Germany

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 10 JUN 2008
  3. Manuscript Accepted: 22 FEB 2008
  4. Manuscript Received: 26 JUN 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (312K)

References

  • 1
    Greiner TC,Medeiros LJ,Jaffe ES. Non-Hodgkin's lymphoma. Cancer 1995; 75: 370–80.
    Direct Link:
  • 2
    Ries LAG,Harkins D,Krapcho M,Mariotto A,Miller BE,Feuer EJ,Clegg L,Eisner MP,Horner MJ,Howlander N,Hayat M,Hankey BF, et al. SEER Cancer Statistics Review 1975–2003, National Cancer Institute. Bethesda, MD, 2006. http://seer.cancer.gov.
  • 3
    Held G,Poschel V,Pfreundschuh M. Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 2006; 6: 1175–86.
  • 4
    Cheson BD. Monoclonal antibody therapy for B-cell malignancies. Semin Oncol 2006; 33: S2–14.
  • 5
    Coiffier B. Monoclonal antibody as therapy for malignant lymphomas. C R Biol 2006; 329: 241–54.
  • 6
    Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359–68.
  • 7
    Mavromatis BH,Cheson BD. Novel therapies for chronic lymphocytic leukemia. Blood Rev 2004; 18: 137–48.
  • 8
    Nagy ZA,Hubner B,Lohning C,Rauchenberger R,Reiffert S,Thomassen-Wolf E,Zahn S,Leyer S,Schier EM,Zahradnik A,Brunner C,Lobenwein K, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 2002; 8: 801–7.
  • 9
    Baeuerle PA,Kufer P,Lutterbuse R. Bispecific antibodies for polyclonal T-cell engagement. Curr Opin Mol Ther 2003; 5: 413–9.
  • 10
    Peipp M,Valerius T. Bispecific antibodies targeting cancer cells. Biochem Soc Trans 2002; 30: 507–11.
  • 11
    Manzke O,Tesch H,Borchmann P,Wolf J,Lackner K,Gossmann A,Diehl V,Bohlen H. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation Int J Cancer 2001; 91: 508–15.
  • 12
    Manzke O,Tesch H,Lorenzen J,Diehl V,Bohlen H. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses. Int J Cancer 2001; 91: 516–22.
    Direct Link:
  • 13
    Haagen IA. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Leuk Lymphoma 1995; 19: 381–93.
  • 14
    Zeidler R,Mysliwietz J,Csanady M,Walz A,Ziegler I,Schmitt B,Wollenberg B,Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83: 261–6.
  • 15
    Zeidler R,Reisbach G,Wollenberg B,Lang S,Chaubal S,Schmitt B,Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163: 1246–52.
  • 16
    Lindhofer H,Menzel H,Gunther W,Hultner L,Thierfelder S. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. Blood 1996; 88: 4651–8.
  • 17
    Ruf P,Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98: 2526–34.
  • 18
    Heiss MM,Strohlein MA,Jager M,Kimmig R,Burges A,Schoberth A,Jauch KW,Schildberg FW,Lindhofer H. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005; 117: 435–43.
    Direct Link:
  • 19
    Riesenberg R,Buchner A,Pohla H,Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 2001; 49: 911–7.
  • 20
    Kiewe P,Hasmuller S,Kahlert S,Heinrigs M,Rack B,Marme A,Korfel A,Jager M,Lindhofer H,Sommer H,Thiel E,Untch M. Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006; 12: 3085–91.
  • 21
    Tedder TF,Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15: 450–4.
  • 22
    O'Keefe TL,Williams GT,Davies SL,Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 1998; 48: 125–32.
  • 23
    Nadler LM,Ritz J,Hardy R,Pesando JM,Schlossman SF,Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981; 67: 134–40.
  • 24
    Delgado J,Matutes E,Morilla AM,Morilla RM,Owusu-Ankomah KA,Rafiq-Mohammed F,del Giudice I,Catovsky D. Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. Am J Clin Pathol 2003; 120: 754–9.
  • 25
    Anderson KC,Bates MP,Slaughenhoupt BL,Pinkus GS,Schlossman SF,Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424–33.
  • 26
    Press OW,Howell-Clark J,Anderson S,Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994; 83: 1390–7.
  • 27
    Lindhofer H,Mocikat R,Steipe B,Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155: 219–25.
  • 28
    Ruf P,Jager M,Ellwart J,Wosch S,Kusterer E,Lindhofer H. Two new trifunctional antibodies for the therapy of human malignant melanoma. Int J Cancer 2004; 108: 725–32.
    Direct Link:
  • 29
    Cochlovius B,Kipriyanov SM,Stassar MJ,Christ O,Schuhmacher J,Strauss G,Moldenhauer G,Little M. Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells. J Immunol 2000; 165: 888–95.
  • 30
    Winkler U,Jensen M,Manzke O,Schulz H,Diehl V,Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab. IDEC-C2B8). Blood 1999; 94: 2217–24.
  • 31
    Bartik MM,Welker D,Kay NE. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 1998; 25: 27–33.
  • 32
    Ghielmini M. Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example. Hematology (Am Soc Hematol Educ Program). 2005: 321–8.
  • 33
    Weiner GJ,De Gast GC. Bispecific monoclonal antibody therapy of B-cell malignancy. Leuk Lymphoma 1995; 16: 199–207.
  • 34
    De Gast GC,Van Houten AA,Haagen IA,Klein S,De Weger RA,Van Dijk A,Phillips J,Clark M,Bast BJ. Clinical experience with CD3 × CD19 bispecific antibodies in patients with B cell malignancies. J Hematother 1995; 4: 433–7.
  • 35
    Huh YO,Keating MJ,Saffer HL,Jilani I,Lerner S,Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001; 116: 437–43.
  • 36
    Reed JC,Kitada S,Kim Y,Byrd J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol 2002; 29: 10–24.
  • 37
    Withoff S,Bijman MN,Stel AJ,Delahaye L,Calogero A,Jonge MW,Kroesen BJ,Leij L. Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells. Br J Cancer 2001; 84: 1115–21.
  • 38
    Xiong D,Xu Y,Liu H,Peng H,Shao X,Lai Z,Fan D,Yang M,Han J,Xie Y,Yang C,Zhu Z. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 × anti-CD3 bispecific diabody. Cancer Lett 2002; 177: 29–39.
  • 39
    Kipriyanov SM,Moldenhauer G,Strauss G,Little M. Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 1998; 77: 763–72.
    Direct Link:
  • 40
    Lin TS,Lucas MS,Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 2003; 30: 483–92.
  • 41
    Nguyen DT,Amess JA,Doughty H,Hendry L,Diamond LW. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62: 76–82.
    Direct Link:
  • 42
    Manzke O,Berthold F,Huebel K,Tesch H,Diehl V,Bohlen H. CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow. Int J Cancer 1999; 80: 715–22.
    Direct Link:
  • 43
    Manzke O,Titzer S,Tesch H,Diehl V,Bohlen H. CD3 × CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma. Cancer Immunol Immunother 1997; 45: 198–202.
  • 44
    Berenson LS,Ota N,Murphy KM. Issues in T-helper 1 development–resolved and unresolved. Immunol Rev 2004; 202: 157–74.
    Direct Link:
  • 45
    Mellstedt H,Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother 2006; 55: 210–20.
  • 46
    Rossi E,Matutes E,Morilla R,Owusu-Ankomah K,Heffernan AM,Catovsky D. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 1996; 10: 494–7.
  • 47
    Dreier T,Lorenczewski G,Brandl C,Hoffmann P,Syring U,Hanakam F,Kufer P,Riethmuller G,Bargou R,Baeuerle PA. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100: 690–7.
    Direct Link:
  • 48
    Loffler A,Gruen M,Wuchter C,Schriever F,Kufer P,Dreier T,Hanakam F,Baeuerle PA,Bommert K,Karawajew L,Dorken B,Bargou RC. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003; 17: 900–9.
  • 49
    Kipriyanov SM,Cochlovius B,Schafer HJ,Moldenhauer G,Bahre A,Le Gall F,Knackmuss S,Little M. Synergistic antitumor effect of bispecific CD19 × CD3 and CD19 × CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J Immunol 2002; 169: 137–44.
  • 50
    Buhmann R,Stanglmaier M,Simoes B,Yang T,Ruf P,Lindhofer H,Kolb HJ. Adoptive immunotherapy of B-cell malignancies with a trifunctinal, bispecific antibody (anti-CD3 × anti-CD20) and allogeneic donor lymphocyte transfusion. Haematologica 2006; 91: 102a.
View Full Article (HTML) Get PDF (312K)